JP2023514721A5 - - Google Patents
Info
- Publication number
- JP2023514721A5 JP2023514721A5 JP2022550151A JP2022550151A JP2023514721A5 JP 2023514721 A5 JP2023514721 A5 JP 2023514721A5 JP 2022550151 A JP2022550151 A JP 2022550151A JP 2022550151 A JP2022550151 A JP 2022550151A JP 2023514721 A5 JP2023514721 A5 JP 2023514721A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980658P | 2020-02-24 | 2020-02-24 | |
| US62/980,658 | 2020-02-24 | ||
| PCT/US2021/019213 WO2021173537A1 (en) | 2020-02-24 | 2021-02-23 | Formulations of anti-endothelial lipase antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023514721A JP2023514721A (ja) | 2023-04-07 |
| JP2023514721A5 true JP2023514721A5 (cg-RX-API-DMAC10.html) | 2024-03-06 |
| JP7892560B2 JP7892560B2 (ja) | 2026-07-21 |
Family
ID=77492003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550151A Active JP7892560B2 (ja) | 2020-02-24 | 2021-02-23 | 抗内皮リパーゼ抗体の製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230131324A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4110290A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7892560B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN115297838A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021227871A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3211692A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TWI887362B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021173537A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| SMP200800064B (it) * | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| PE20120359A1 (es) | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| WO2013086443A1 (en) * | 2011-12-08 | 2013-06-13 | Amgen Inc. | Agonistic human lcat antigen binding proteins and their use in therapy |
| US20150239970A1 (en) * | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| US9932591B2 (en) * | 2013-12-18 | 2018-04-03 | University Of Delaware | Reduction of lipase activity in product formulations |
| CN106604744A (zh) * | 2014-09-03 | 2017-04-26 | 免疫医疗有限公司 | 稳定的抗IL‑4R‑α抗体配制品 |
| TWI734410B (zh) * | 2014-09-11 | 2021-07-21 | 日商塩野義製藥股份有限公司 | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
-
2021
- 2021-02-23 CN CN202180016623.6A patent/CN115297838A/zh active Pending
- 2021-02-23 WO PCT/US2021/019213 patent/WO2021173537A1/en not_active Ceased
- 2021-02-23 US US17/801,670 patent/US20230131324A1/en active Pending
- 2021-02-23 AU AU2021227871A patent/AU2021227871A1/en active Pending
- 2021-02-23 JP JP2022550151A patent/JP7892560B2/ja active Active
- 2021-02-23 EP EP21760163.2A patent/EP4110290A4/en active Pending
- 2021-02-23 CA CA3211692A patent/CA3211692A1/en active Pending
- 2021-02-24 TW TW110106493A patent/TWI887362B/zh active